Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths in the United States. Although chemotherapeutic regimens such as gemcitabine+ nab-paclitaxel and FOLFIRINOX (FOLinic acid, 5-Fluroruracil, IRINotecan, and Oxaliplatin) significantly improve patient survival,...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Aditi, Bhardwaj, Vikas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554400/
https://www.ncbi.nlm.nih.gov/pubmed/34754151
http://dx.doi.org/10.3748/wjg.v27.i39.6527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554400/
https://www.ncbi.nlm.nih.gov/pubmed/34754151
http://dx.doi.org/10.3748/wjg.v27.i39.6527

Ejemplares similares